by 
The global High Content Screening market is estimated to be valued at US$ 1,847.2 Mn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
High content screening is a cell-based analytical technique that allows imaging and analysis of cell features such as morphology, translocation, and protein expression into multiple cellular compartments simultaneously. High content screening offers several advantages over traditional methods such as ELISA or western blot. It enables non-destructive, multi-parametric analysis of large numbers of samples in a highly parallel format and provides quantitative data on cellular processes under normal and perturbed conditions. The technology has enabled researchers to obtain a wealth of information from a single experiment which has greatly enhanced drug discovery and disease modeling efforts.
Market key trends:
Increasing R&D investments in the pharmaceutical and biotechnology industries is a major factor driving growth of the high content screening market. According to research, pharmaceutical companies are likely to spend over US$ 150 Bn on R&D by 2023. Growing focus on cell-based assay systems for early assessment of drug toxicity and efficacy is also fueling demand for high content screening systems. Technological advancement has led to development of high-throughput and high-content screening platforms with improved image acquisition, analysis and storage capabilities. Growing stem cell and cancer research worldwide also presents significant growth opportunities. In addition, increasing focus on personalized medicine and companion diagnostics offer new growth avenues over the forecast period. However, high cost of instruments remains a major challenge.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low due to the high investments needed for research and development activities as well as huge production costs. However, the increasing funding from public and private organizations is providing opportunities to new players.
Bargaining power of buyers: The bargaining power of buyers is high due to the presence of a large number of pharmaceutical and biotechnology companies globally. Buyers can negotiate on price as there are many players operating in the market.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are few component manufacturers for instruments and consumables used in high content screening. However, suppliers have threat to forward integrate.
Threat of new substitutes: The threat of new substitutes is low as HCS systems provide unique advantages over other screening techniques like high-throughput screening. However, the development of advanced single-cell analysis tools poses a threat.
Competitive rivalry: High due to the presence of major global players and new entrants with novel solutions.
Key Takeaways
The global High Content Screening market is expected to witness high growth, exhibiting CAGR of 5.8% over the forecast period, due to increasing R&D investments made by pharmaceutical and biotechnology companies for drug discovery.
Regional analysis: North America dominated the global high content screening market in 2022 and is expected to maintain its dominance over the forecast period. This is attributed to increasing government initiatives and funding for life science research in the region. However, Asia Pacific is expected to grow at the fastest pace owing to rising investments by key players and growing focus of pharmaceutical companies in the region.
Key players operating in the high content screening market are Becton, Dickinson and Company, Thermo Fisher Scientific Inc., GE HealthCare, Olympus Corporation, PerkinElmer Inc., Merck Millipore Corporation, Danaher, Yokogawa Electric Corporation, Sysmex Corporation, and Thorlabs, Inc. Key players are focusing on new product launches and expansion strategies to strengthen their market position. For instance, in 2022, Thermo Fisher launched new Opera Phenix high-content screening system to accelerate assays for drug discovery and screening applications.
